{"id":389989,"date":"2021-08-02T00:00:00","date_gmt":"2021-08-02T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0017-2021-biopharma-psoriasis-access-and-reimbursement-us-2021\/"},"modified":"2026-04-21T11:23:24","modified_gmt":"2026-04-21T11:23:24","slug":"acreim0017-2021-biopharma-psoriasis-access-and-reimbursement-us-2021","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0017-2021-biopharma-psoriasis-access-and-reimbursement-us-2021\/","title":{"rendered":"Psoriasis | Access and Reimbursement | US | 2021"},"content":{"rendered":"<p>Tumor necrosis factor-alpha (TNF-\u03b1) inhibitors (e.g., AbbVie\u2019s Humira, Amgen\u2019s Enbrel) and Janssen\u2019s interleukin (IL)-12\/23 inhibitor Stelara have been leading the U.S. psoriasis biologics market, but the approval of novel, effective therapies has started changing the landscape as newer biologics gain greater acceptance from treating physicians. Novartis\u2019s IL-17 inhibitor Cosentyx and Amgen\u2019s oral phosphodiesterase (PDE)-4 inhibitor Otezla have successfully carved out space in the treatment algorithm. More-effective biologics\u2014AbbVie\u2019s Skyrizi, Janssen\u2019s Tremfya, and Eli Lilly\u2019s Taltz\u2014are threatening TNF-\u03b1 inhibitors\u2019 first-line dominance. Given the recent entry of biosimilars and the late-phase development of an IL-17 A\/F dual inhibitor, an oral tyrosine kinase 2 (TYK2) inhibitor, and two novel topical therapies, marketers of psoriasis therapies must learn how to navigate this increasingly competitive market.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What are the current patient-share leaders among psoriasis biologics \/ Otezla, and which psoriasis agents do physicians and payers perceive to perform best on specific clinical and market access factors?<\/li>\n<li>How do payers cover biosimilar versions of infliximab (Pfizer\u2019s Inflectra, Merck\u2019s Renflexis), and what is physicians\u2019 expected prescribing of biosimilars?<\/li>\n<li>What are physician perceptions of emerging therapies such as bimekizumab, Remsima (SC), and deucravacitinib and emerging nonsteroidal topical agents with novel mechanisms of action? How do payers anticipate covering these agents?<\/li>\n<li>What pharmacoeconomic models and data do payers value given the likely cost and efficacy of novel psoriasis agents?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>U.S. Access &#038; Reimbursement<\/em> provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment, including up-to-date analysis of drug coverage and restriction policies and payer and prescriber perspectives on key marketed drugs and receptivity to emerging therapies.<\/p>\n<p><strong>Key Drugs: <\/strong><strong>B<\/strong>imekizumab, Cimzia, Cosentyx, deucravacitinib, Enbrel, Humira, Ilumya, Inflectra, Otezla, Remicade, Remsima (SC), Renflexis, roflumilast (topical), Siliq, Skyrizi, Stelara, Tremfya, tapinarof.<\/p>\n<p><strong>Key Companies: <\/strong>AbbVie, Amgen, Arcutis, Bristol-Myers Squibb, Dermavant, Eli Lilly, Janssen, Merck, Pfizer, Novartis, UCB.<\/p>\n","protected":false},"template":"","class_list":["post-389989","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-psoriasis","biopharma-geography-us","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389989","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389989\/revisions"}],"predecessor-version":[{"id":576384,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389989\/revisions\/576384"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389989"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}